Darolutamide and health-related QoL in ARAMIS
Oncología

Darolutamide and health-related quality of life in patients with nonmetastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

Smith M. et al. European Journal of Cancer 2021:154;138-146

Related Content
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guías 2022 I
Cáncer de próstata
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guías 2022 II
Cáncer de próstata
CPRCnm: recomendaciones de manejo
CPRCnm